Merck announces its investigational CETP-Inhibitor, MK-0859, produced positive effects on lipids with no observed blood pressure changes
In Phase IIb study results presented by Merck, anacetrapib (formerly known as MK-0859), its investigational selective cholesteryl ester transfer protein inhibitor, significantly reduced LDL-cholesterol and Apolipoprotein B and increased HDL-cholesterol and Apolipoprotein A-1 both as monotherapy and in combination with atorvastatin 20 mg compared to placebo in patients with dyslipidemia. These results were presented today at the 16th International Symposium on Drugs Affecting Lipid Metabolism. The primary endpoint of the eight-week study was LDL-C reduction, with secondary endpoints of HDL-C increases and effects on other lipoproteins and apolipoproteins and blood pressure evaluated across ten treatment groups. In the study, anacetrapib monotherapy at doses of 10 mg, 40 mg, 150 mg and 300 mg reduced LDL-C levels by 16 percent, 27 percent, 40 percent, and 39 percent, and increased HDL-C levels by 44 percent, 86 percent, 139 percent, and 133 percent compared to placebo (two and four percent, respectively) in a dose dependent manner. Anacetrapib co-administered with atorvastatin, across all doses studied, also produced significant incremental reductions in LDL-C and increases in HDL-C compared to atorvastatin alone. The comparative lipid results in the study were statistically significant (p<0.001 vs. placebo for all doses).